

### **Confirmation Statement**

Company Name: AVVINITY THERAPEUTICS LIMITED

Company Number: 09967702

X5ZHFFOR

Received for filing in Electronic Format on the: 03/02/2017

Company Name: AVVINITY THERAPEUTICS LIMITED

Company Number: 09967702

Confirmation 24/01/2017

Statement date:

Sic Codes: **72110** 

Principal activity Research and experimental development on biotechnology

description:

### **Statement of Capital (Share Capital)**

Class of Shares: A Number allotted 500000

ORDINARY Aggregate nominal value: 500

Currency: GBP

Prescribed particulars

THE PRESCRIBED PARTICULARS OF RIGHTS ATTACHED TO THE A ORDINARY SHARES (THE "'A' SHARES") ARE: 1. THE HOLDERS OF 'A' SHARES ARE ENTITLED TO APPOINT UP TO TWO PERSONS TO BE (HE 'A' DIRECTORS OF THE COMPANY. 2. THE HOLDERS OF 'A' SHARES ARE ENTITLED TO APPOINT, IN AGGREGATE, UP TO ONE DULY AUTHORISED REPRESENTATIVE TO ATTEND (WHETHER IN PERSON OR BY PROXY) AND VOTE AT GENERAL MEETINGS OF THE COMPANY. 3. THE QUORUM AT ANY GENERAL MEETING OF THE COMPANY, OR ADJOURNED GENERAL MEETING, IS TWO PERSONS PRESENT IN PERSON OR BY PROXY, OF WHOM ONE MUST BE A DULY AUTHORISED REPRESENTATIVE OF THE HOLDERS OF A1 SHARES. 4. ANY RESOLUTION TO BE VOTED AT A GENERAL MEETING SHALL NOT BE PASSED WITHOUT UNANIMOUS APPROVAL, SUCH THAT THE DULY APPOINTED REPRESENTATIVE OF THE HOLDERS OF 'A1 SHARES IS REQUIRED. 5. ON A DISTRIBUTION OF ASSETS ON A LIQUIDATION OR A RETURN OF CAPITAL OCCURRING BEFORE 28 FEBRUARY 2019 (OTHER THAN FOLLOWING AN ASSET SALE), THE SURPLUS ASSETS OF THE COMPANY ARE FIRST APPLIED IN PAYING TO THE HOLDERS OF THE 'B1 SHARES, IN PRIORITY, AN AMOUNT EQUAL TO THE PRICE PER 'B' SHARE AND THE BALANCE OF THE SURPLUS ASSETS (IF ANY) IS THEN APPLIED TO PAYING TO THE HOLDERS OF THE 'A1 SHARES AN AMOUNT EQUAL TO THE AMOUNT DISTRIBUTED TO THE HOLDERS OF THE 'B' SHARES OROVIDED THAT IF THERE ARE INSUFFICIENT SURPLUS ASSETS TO PAY SUCH AMOUNT. ALL OF THE REMAINING SURPLUS ASSETS ARE DISTRIBUTED TO THE LOLDERS OF THE 'A' SHARES. ON A DISTRIBUTION OF ASSETS ON A IQUIDATION OR A RETURN OF CAPITAL OCCURRING AFTER 28 FEBRUARY 2019 )R WHICH FOLLOWS THE SALE OF ALL OR SUBSTANTIALLY ALL OF THE ASSETS OF HE COMPANY. THE SURPLUS ASSETS OF THE COMPANY ARE DISTRIBUTED AMONG THE HOLDERS OF THE SHARES PRO RATA TO THE NUMBER OF SHARES LELD. I. EXCEPT AS OTHERWISE PROVIDED, THE 'A' SHARES CARRY THE SAME RIGHTS AND PRIVILEGES AND RANK PARI PASSU WITH ALL OTHER ORDINARY SHARES IN ALL RESPECTS, BUT CONSTITUTE SEPARATE CLASSES OF SHARES.

Class of Shares: B Number allotted 250000

**ORDINARY** Aggregate nominal value: 250

**GBP** Currency:

Prescribed particulars

THE PRESCRIBED PARTICULARS OF RIGHTS ATTACHED TO THE B ORDINARY SHARES (THE "'B' SHARES") ARE: 1. THE HOLDERS OF 'B' SHARES ARE ENTITLED TO APPOINT UP TO TWO PERSONS TO BE THE 'B! DIRECTORS OF THE COMPANY. 2. THE HOLDERS OF 'B' SHARES ARE ENTITLED TO APPOINT. IN AGGREGATE. UP TO ONE DULY AUTHORISED REPRESENTATIVE TO ATTEND (WHETHER IN PERSON OR BY PROXY) AND VOTE AT GENERAL MEETINGS OF THE COMPANY. 3. THE QUORUM AT ANY GENERAL MEETING OF THE COMPANY, OR ADJOURNED GENERAL MEETING, IS TWO PERSONS PRESENT IN PERSON OR BY PROXY, OF WHOM ONE MUST BE A DULY AUTHORISED REPRESENTATIVE OF THE HOLDERS OF 'B\* SHARES 4. ANY RESOLUTION TO BE VOTED AT A GENERAL MEETING SHALL NOT BE PASSED WITHOUT UNANIMOUS APPROVAL. SUCH THAT THE DULY APPOINTED REPRESENTATIVE OF THE HOLDERS OF'B' SHARES IS REQUIRED. 5. ON A DISTRIBUTION OF ASSETS ON A LIQUIDATION OR A RETURN OF CAPITAL OCCURRING BEFORE 28 FEBRUARY 2019 (OTHER THAN FOLLOWING AN ASSET SALE), THE SURPLUS ASSETS OF THE COMPANY ARE FIRST APPLIED IN PAYING TO THE HOLDERS OF THE 'B' SHARES, IN PRIORITY, AN AMOUNT EQUAL TO THE PRICE PER 'B' SHARE AND THE BALANCE OF THE SURPLUS ASSETS (IF ANY) IS THEN APPLIED TO PAYING TO THE HOLDERS OF THE 'A' SHARES AN AMOUNT EQUAL TO THE AMOUNT DISTRIBUTED TO THE HOLDERS OF THE 'B' SHARES PROVIDED THAT IF THERE ARE INSUFFICIENT SURPLUS ASSETS TO PAY SUCH AMOUNT, ALL OF THE REMAINING SURPLUS ASSETS ARE DISTRIBUTED TO THE HOLDERS OF THE W SHARES. ON A DISTRIBUTION OF ASSETS ON A LIQUIDATION OR A RETURN OF CAPITAL OCCURRING AFTER 28 FEBRUARY 2019 OR WHICH FOLLOWS THE SALE OF ALF OR SUBSTANTIALLY ALL OF THE ASSETS OF THE COMPANY. THE SURPLUS ASSETS OF THE COMPANY ARE DISTRIBUTED AMONG THE HOLDERS OF THE SHARES PRO RATA TO THE NUMBER OF SHARES HELD. 3. EXCEPT AS OTHERWISE PROVIDED. THE 'B' SHARES CARRY THE SAME IGHTS AND PRIVILEGES AND RANK PARI PASSU WITH ALL OTHER ORDINARY SHARES IN ALL RESPECTS. BUT CONSTITUTE SEPARATE CLASSES OF SHARES.

Statement	of	Capital	(Totals)
-----------	----	---------	----------

Currency: **GBP** Total number of shares: 750000

> Total aggregate nominal 750

09967702

value:

	Total aggregate amount	0
	unpaid:	
Electronically filed document for Company Number:	09967702	
,		

### **Full details of Shareholders**

The details below relate to individuals/corporate bodies that were shareholders during the review period or that had ceased to be shareholders since the date of the previous confirmation statement.

Shareholder information for a non-traded company as at the confirmation statement date is shown below

Shareholding 1: 500000 A ORDINARY shares held as at the date of this confirmation

statement

Name: **CENTAURI THERAPEUTICS LIMITED** 

Shareholding 2: 250000 B ORDINARY shares held as at the date of this confirmation

statement

Name: HORIZON DISCOVERY GROUP PLC

## **Persons with Significant Control (PSC)**

#### **PSC** notifications

**Notification Details** 

Date of becoming a registrable RLE:

06/04/2016

Name: CENTAURI THERAPEUTICS LIMITED

Registered or Principal

1ST FLOOR THAVIES INN HOUSE 3-4 HOLBORN CIRCUS

Office Address:

LONDON ENGLAND EC1N 2HA

Legal Form: PRIVATE LIMITED COMPANY

Governing Law: COMPANIES ACT

Register: ENGLAND AND WALES

Country/state of register: ENGLAND

Registration Number: 08879741

#### **Nature of control**

The relevant legal entity holds, directly or indirectly, more than 50% but less than 75% of the shares in the company.

#### **Notification Details**

Date of becoming a registrable RLE:

06/04/2016

Name: HORIZON DISCOVERY GROUP PLC

Registered or Principal

Office Address:

**BUILDING 8100 CAMBRIDGE RESEARCH PARK, BEACH** 

**DRIVE** 

WATERBEACH CAMBRIDGE ENGLAND CB25 9TL

Legal Form: PUBLIC LIMITED COMPANY

Governing Law: COMPANIES ACT

Register: ENGLAND AND WALES

Country/state of register: ENGLAND

Registration Number: 08921143

#### Nature of control

The relevant legal entity holds, directly or indirectly, more than 25% but not more than 50% of the shares in the company.

# **Confirmation Statement**

I confirm that all information required to be delivered by the company to the registrar in relation to
the confirmation period concerned either has been delivered or is being delivered at the same time as the confirmation statement

09967702

**Electronically filed document for Company Number:** 

## **Authorisation**

Authenticated  This form was authorized by one of the following:
This form was authorised by one of the following: Director, Secretary, Person Authorised, Charity Commission Receiver and Manager, CIC Manager, Judicial Factor

09967702

End of Electronically filed document for Company Number: